梅斯健康(02415.HK)中期毛利7750萬元 同比增長14.1%
格隆匯8月29日丨梅斯健康(02415.HK)公吿,截至2025年6月30日止六個月,集團實現總收益人民幣125.2百萬元,同比增長13.2%;毛利77.5百萬元,同比增長14.1%;淨利潤13.2百萬元,同比增長5,238.3%。業績增長主要受益於行業復甦帶動多渠道精準營銷需求攀升,以及企業對循證驅動型營銷模式的加速轉型;毛利及淨利的增長,得益於AI驅動的智能化運營體系建設帶來的效率提升及銷售策略優化。尤其值得一提的是,報吿期內AI相關業務收入已達人民幣5.6百萬元,成為集團新增長曲線的重要來源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.